I mentioned yesterday that if the recent no-licence fee and no-milestone fee research agreement with Medicxi was anything more than a footnote in the QR it should be a cause for concern. And yep, there we have it front and centre in the first paragraph.
Three months ago I guesstimated an end of Q cash balance of $26.5 million. Was almost spot on with Starpharma reporting a balance of $26.6m.
A very concerning QR for long suffering shareholders IMO. Sentiment changed to SELL.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-4
-
- There are more pages in this discussion • 50 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $43.29M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 10.0¢ | $12.03K | 116.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3000 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 109616 | 3 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| SPL (ASX) Chart |